Related Experiment Video

Updated: Jun 8, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis

D Aarsland1, K Bronnick, C Williams-Gray

  • 1Stavanger University Hospital, Psychiatric Division, PO Box 8100, 4068 Stavanger, Norway. daarsland@gmail.com

Neurology
|September 22, 2010
PubMed
Abstract

Insights

Mild cognitive impairment (MCI) affects over a quarter of Parkinson disease (PD) patients without dementia, impacting memory and other cognitive functions. Understanding MCI profiles in PD is crucial for future research and interventions.

Area of Science:

  • Neurology
  • Cognitive Science
  • Neurodegenerative Diseases

Background:

  • Mild cognitive impairment (MCI) prevalence and profiles in Parkinson disease (PD) patients without dementia vary significantly across studies.
  • Methodological differences are likely responsible for observed discrepancies in MCI research within PD cohorts.

Purpose of the Study:

  • To establish the frequency and detailed cognitive profile of MCI in a large, multicenter cohort of well-defined Parkinson disease patients.
  • To utilize a standardized analytical method and a common definition for MCI to ensure consistency.

Main Methods:

  • Included 1,346 Parkinson disease patients from 8 distinct cohorts.
  • Performed standardized assessments of verbal memory, visuospatial abilities, and attentional/executive functions.
  • Defined MCI based on age- and education-corrected z scores at least 1.5 standard deviations below the mean in one or more cognitive domains.

Main Results:

  • Mild cognitive impairment (MCI) was identified in 25.8% of Parkinson disease (PD) patients.
  • Memory impairment was the most frequent (13.3%), followed by visuospatial (11.0%) and attention/executive (10.1%) deficits.
  • MCI was associated with older age, male gender, depression, motor symptom severity, and advanced disease stage.

Conclusions:

  • Mild cognitive impairment (MCI) is prevalent in Parkinson disease (PD) patients without dementia, affecting multiple cognitive domains.
  • Further research should focus on identifying risk factors for cognitive decline and evaluating interventions for MCI in PD at a predementia stage.

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...